Cullinan presents CLN-978 Phase 1 data showing clinical benefit in SLE and RA patients

Cullinan Therapeutics announced initial clinical data for CLN-978, a CD19xCD3 T cell engager, demonstrating remissions in lupus and rheumatoid arthritis patients with a favorable safety profile. The positive Phase 1 results support advancement of the drug through clinical development for autoimmune diseases with significant unmet medical need.